Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Montanide ISA 51 | ||||
Sargramostim | Leukine | GM-CSF|Prokine | ||
SurVaxM | SVN53-67/M57-KLH | SurVaxM (SVN53-67/M57-KLH) is a peptide vaccine targeting survivin (Birc5), which may induce anti-tumor immune response (PMID: 27576783). | ||
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05163080 | Phase II | SurVaxM + Temozolomide Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE) | Active, not recruiting | USA | 0 |